Sector Expert: Leo Ehrlich
Leo Ehrlich, CPA, is a cofounder of Cellceutix and has served as CFO and director since inception in June 2007 and as CEO since November 2010. Ehrlich has more than 25 years of executive leadership experience in building and managing emerging growth companies. Prior to Cellceutix, he served as CFO and director of Nanoviricides, a publicly traded company developing nanotechnology-based anti-viral medicines. Prior to that, Ehrlich held numerous executive positions, including CEO, president, CFO, and director at StatSure Diagnostic Systems Inc., a diagnostic company in the HIV space. Ehrlich is a certified public accountant and received his BBA from Bernard Baruch College of the City University of New York.
A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen (1/27/16)
Drug development seems to move at a snail's pace, but Cellceutix Corp.'s CEO Leo Ehrlich says his company has jumped through the most time-consuming hoops of development and now has a diversified pipeline with three main drug candidates, any of which could become the lead program with new data in 2016. Ehrlich and Chief Medical Officer Dr. Daniel Jorgensen, an infectious disease specialist, discuss the candidates, beginning with the first new class of antibiotics to enter Phase 3 in skin infections in decades.